Vertex Pharmaceuticals Incorporated

🇺🇸NASDAQ Global Select
Back to all articles
Vertex Pharmaceuticals Incorporated stock analysis VRTX overview
Somewhat Bearish -25

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

📅 Vertex Pharmaceuticals (VRTX) is expected to report quarterly earnings for the quarter ended March 2026 on May 4.

💰 Analysts forecast quarterly earnings per share of $4.20, representing a year-over-year increase of 3.5%.

📈 Revenue is projected to reach $2.98 billion, marking a 7.7% growth compared to the same quarter last year.

📉 The consensus EPS estimate has been revised 0.36% lower over the past 30 days reflecting bearish sentiment.

🔍 Zacks Earnings ESP analysis shows Vertex currently has a negative reading of -0.54%, making an earnings beat less likely.

⚠️ Vertex's stock carries a Zacks Rank of #3 (Hold), which combined with the negative ESP reduces confidence in a surprise beat.

📊 In the last reported quarter, Vertex missed estimates by 0.79% and has only beaten consensus EPS twice in the trailing four quarters.

⚖️ Stock price direction depends not only on earnings results but also on management commentary during the earnings call.

🧬 Alnylam Pharmaceuticals (ALNY) serves as a comparable peer expected to report strong revenue growth of 90.9% this quarter.

📈 Alnylam has a positive Earnings ESP of +12.80% and a Zacks Rank of #3, indicating a higher likelihood of beating estimates.

🏆 Alnylam has achieved an earnings beat in each of its trailing four quarters compared to Vertex's mixed track record.

🛠️ Investors are encouraged to utilize the Zacks Earnings ESP Filter to identify stocks with better odds before earnings releases.

Bullish Signals
  • Vertex Pharmaceuticals is expected to deliver year-over-year growth in both earnings and revenues when it reports results for the quarter ended March 2026.
  • Analysts project quarterly earnings of $4.20 per share, representing a positive year-over-year increase of +3.5%.
  • Revenues are forecast to reach $2.98 billion, which is up 7.7% from the year-ago quarter, indicating strong top-line expansion.
  • Vertex carries a Zacks Rank of #3, which suggests the stock has potential for maintaining solid performance despite recent estimate revisions.
  • Historical data shows that Vertex beat consensus EPS estimates two times in the last four quarters, demonstrating consistent earnings delivery capability.
Risk Factors
  • The consensus EPS estimate for Vertex has been revised 0.36% lower over the last 30 days, indicating analysts have recently become bearish on the company's earnings prospects.
  • Vertex currently carries a Zacks Rank of #3 (Hold), which makes it difficult to conclusively predict that the company will beat its consensus EPS estimate.
  • The Most Accurate Estimate for Vertex is lower than the Zacks Consensus Estimate, resulting in a negative Earnings ESP of -0.54% that does not signal an earnings miss.
  • Vertex's surprise history shows it missed consensus expectations in the last reported quarter with earnings of $5.03 per share versus an expected $5.07 per share.
  • Over the last four quarters, the company has beaten consensus EPS estimates only two times, suggesting a lack of consistent outperformance.
Full Analysis
Vertex Pharmaceuticals (VRTX) is poised to report quarterly earnings for the period ended March 2026 on May 4, with market expectations set for a year-over-year increase in both revenues and earnings. Analysts project quarterly earnings of $4.20 per share, representing a 3.5% rise from the prior year, while revenues are anticipated to reach $2.98 billion, marking a 7.7% increase. Over the past 30 days, the consensus EPS estimate has been revised downward by 0.36%, reflecting analysts reassessing their initial projections and becoming somewhat more bearish on the company's near-term earnings prospects. The Zacks Investment Research model analyzes these dynamics using its Earnings ESP (Expected Surprise Prediction) and Zacks Rank to forecast potential stock movement. For Vertex, the Most Accurate Estimate sits lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.54%, which makes predicting an earnings beat difficult according to proprietary research. The company currently holds a Zacks Rank of #3 (Hold). Historical performance indicates that over the last four quarters, Vertex has beaten consensus EPS estimates only two times, with the most recent reported quarter showing a minor miss at -$5.07 vs $5.03, resulting in a -0.79% surprise. While an earnings beat is a key driver for stock price movement, other factors influencing the outcome cannot be ruled out, as many stocks have experienced declines despite beating expectations due to disappointing business commentary or missed guidance. The article suggests that betting solely on anticipated beats increases odds of success but does not guarantee it. Conversely, Vertex's current metrics do not make it a compelling candidate for an earnings beat based on the Zacks criteria. In comparison, peer Alnylam Pharmaceuticals (ALNY) is expected to report EPS of $1.43 with revenues of $1.13 billion, carrying a positive Earnings ESP of +12.80% and a consistent history of beating estimates in all four trailing quarters, though it faces similar macroeconomic considerations ahead of its own earnings release.